Myocardial no-reflow in humans.

By G. Niccoli, F. Burzotta, L. Galiuto, F. Crea. Journal of the American College of Cardiology, 2009

827 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/76ed7d454eba0faf207a84507ddb621627b00cd2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Krenz
2. B. J. Gersh
3. G. Heusch
4. Ronald J. Korthuis
5. Christopher P. Baines
6. Theodore J Kalogeris

Citations in the corpus

• Cell Biology of Ischemia/Reperfusion Injury (2012, methodology): “No-reflow occurs in a variable proportion of patients following percutaneous coronary intervention (PCI) for myocardial ischemia, ranging from 5% to 50%, and is an independent predictor of adverse outcome (Niccoli et al., 2009).”
• The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. (2016, background): “morrhage, are powerful and clinically important adverse prognostic factors.(74,77) – 79 The causal relationship between myocardial and”
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, neutral): “mation, endothelial injury, edema, atheroembolization, vasospasm, and myocyte reperfusion injury.(220) No-reflow”
• Ischemia/Reperfusion (2016, neutral): “devices versus and pharmacologic pre- and postconditioning strategies) to limit reperfusion injury (586, 587, 625, 697).”